Multicentric Castleman's disease in HIV infection

International Journal of STD and AIDS

Volumn 17, Issue 1, 2006, Pages 19-26

  Collins, L S ^a,b   Fowler, A ^a   Tong, C Y W ^a   De Ruiter, A ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

HHV8; Lymphoproliferative disorder; Multicentric Castleman's disease; Non Hodgkin's lymphoma

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; CORTICOSTEROID; ETOPOSIDE; GANCICLOVIR; HUMAN IMMUNOGLOBULIN; INTERLEUKIN 6; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD 20; RITUXIMAB; UNCLASSIFIED DRUG;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL ACTIVITY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOMEGALIC INCLUSION BODY DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; TRANSPLANT COORDINATOR;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; MALE;

EID: 30944458175     PISSN: 09564624     EISSN: 09564624     Source Type: Journal    
DOI: 10.1258/095646206775220496     Document Type: Review

References (46)

1. Castleman B, Iverson L, Menendez VP. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956;9:822-30
2. Herrada J, Cabarillas F, Rice L, Manning J, Pugh W. The clinical behaviour of localized and multicentric Castleman disease. Ann Intern Med 1998;128:657-62
3. Soulier J, Grollet L, Oksenhelder E, et al. Kaposi's sarcoma-associated herpes virus-like DNA sequences in multicentric Castleman's disease. Blood 1995;86:1276-80
4. Gaba AR, Stein DL, Variakojis D. Multicentric giant lymph node hyperplasia. Am J Clin Pathol 1978;69:86-90
5. Lachant NA, Sun NC, Leong LA, Oseas RS, Prince HE. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 1985;83:27-33
6. Oksenhelder E, Boulanger E, Galicier L, et al. High incidence of Kaposi's sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman's disease. Blood 2002;99:2331-6
7. Oksenhelder E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996;10:61-7
8. Frizzera G, Banks PM, Massarelli G, Rosai J. A systemic lymphoproliferative disorder with morphological features of Castleman's disease. Am J Surg Pathol 1983;7:211-31
9. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993;20:636-47
10. Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 1972;29:670-82
11. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-6 in Castleman's disease. Blood 1989;74:1360-7
12. Pantoleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of the disease. Nature 1993;362:355-8
13. Weisenburger DD, Nathwani BN, Winburg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathological study of 16 cases. Hum Pathol 1985;16:162-72
14. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes virus-like DNA sequence in AIDS associated Kaposi's sarcoma. Science 1994;266:1865
15. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in HIV type 1-infected patients with MCD are associated with a high increase in Kaposi's sarcoma herpes virus DNA load in PBMCs. J Infect Dis 1997;175:1198-201
16. Boivin G, Cote S, Cloutier N, Abed Y, Maguigad M, Routy JP. Quantification of HHV8 by realtime PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol 2002; 68:399-403
17. Burger R, Neipel F, Fleckenstein B, et al. Human herpesvirus type 8 interleukin-6 homologue is functionally active on human myeloma cells. Blood 1998;92:1858-63
18. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma associated herpes virus-encoded interleukin 6. Blood 1999;93:4034-43
19. Oksenhelder E, Carcelain G, Aoki Y, et al. High levels of human herpes virus 8 load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood 2000;96:2069-73
20. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV v-IL6, in HIV seronegative Castleman's disease. Am J Pathol 1998;6:1517-22
21. Parravicini C, Chandran B, Corbellino M. Differential viral protein expression in KS associated herpesvirus infected diseases: KS, primary effusion lymphoma and multicentric Castleman's disease. Am J Pathol 2000;156:743-9
22. Dupin N, Fisher C, Kellam P, et al. Distribution of HHV8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999;96:4546-51
23. Dupin N, Diss TL, Kellam P, et al. HHV8 is associated with a plasmablastic variant of Castleman's disease that is linked to HHV8 positive plasmablastic lymphoma. Blood 2000;95:1406-12
24. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castlemans disease: a report of 16 cases and a review of the literature. Cancer 2001;92:670-6
25. Scott D, Cabral L, Harrington WJ. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001;66:148-50
26. Loi S, Goldstein D, Clezy K, Milliken ST, Hoy J, Chipman M. Castleman's disease and HIV infection in Australia. HIV Med 2004;5:157-62
27. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpes virus 8-positive Castleman disease in human immunodeficiency virus infected patients: the impact of HAART. Clin Infect Dis 2002;35:880-2
28. Lanzafarme M, Carretta G, Trevenzoli M, Lazzarini L, Concia SVE. Successful treatment of Castleman's disease with HAART in two HIV-infected patients (Letter). J Infect 2000;40:90-1
29. Dupin N, Krivine A, Calvez V, Gorin I, Franck N, Escande JP. No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient. AIDS 1997;11:1400-1
30. Zietz C, Bognor JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999;340:1923-4
31. Coty P, Astrow A, Gallinson D, et al. Splenectomy is an effective treatment for HIV-associated Castleman's Disease. Paper Presented at 7th International Conference on Malignancies in AIDS and Other Immunodeficiencies. Bethesda, MD, 28-29 April 2003, Abstract No. 11
32. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma associated herpesvirus replication to antiviral drugs. J Clin Invest 1997;99:2082-6
33. Alice B, Felix A, Eric O. Failure of cidofovir in HIV-associated multicentric Castleman's disease (correspondence). Blood 2004;103:4368-9
34. Corey CW, Garrett N, Meei-Li H, Lawrence C, Anna W. Remission of HHV8 and HIV-associated multicentric Castleman disease with ganciclovir treatment. Blood 2004;103:1632-4
35. Revuelta M, Nord JA. Successful treatment of multicentric Castleman's disease in a patient with HIV. Clin Infect Dis 1998;26:527
36. Bottieau E, Colebunders A, Schroyens W, et al. Multicentric Castleman's disease in 2 patients with HIV infection unresponsive to antiviral therapy. Acta Clin Belg 2000;55:97-101
37. Corbellino M, Bestetti G, Scalamogna C, et al. Long term remission of KSHV related multicentric Castleman's disease with anti-CD20 monoclonal antibody therapy. Blood 2001;98:3473-5
38. Marcelin A, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003;102:2786-8
39. Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferon alpha. Clin Infect Dis 2000;31:602-4
40. Nord JA, Karter D. Low dose interferon alpha therapy for HIV associated multicentric Castleman's disease. Int J STD AIDS 2003;14:61-2
41. Beck JT, Hsu SM, Wijsenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med 1994;330:602-5
42. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanised anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61
43. Singhal S, Mehta J, Desikan R, et al. Antitumour activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71
44. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003;73:48-53
45. Jung C, Emmerich B, Goebel F, Bogner J. Successful treatment of a patient with HIV associated multicentric Castleman's disease with thalidomide. Am J Hematol 2004;75:176-8
46. Bourboulia D, Aldam D, Lagos D, et al. Short and longterm effects of HAART on Kaposi's sarcoma associated herpes virus immune responses and viraemia. AIDS 2004;18:485-93